Skip to main content

Market Overview

Analysts Diverge On Celgene's Deal With Juno Therapeutics

Analysts Diverge On Celgene's Deal With Juno Therapeutics

Whether Celgene Corporation (NASDAQ: CELG) went too far in its $1 billion development deal with Juno Therapeutics Inc (NASDAQ: JUNO) is a matter for speculation.

Celgene unveiled an agreement late Monday in which it will pay Juno $150 million and acquire about $850 million in Juno shares in exchange for development rights to part of Juno's pipeline.

See Also: Juno Therapeutics Signs $1 Billion Development Pact With Celgene

"It's a hefty premium for assets that are difficult to value," said Morgan Stanley's Matthew Harrison, who didn't offer a rating on Celgene.

But JMP's Michael G. King Jr said the deal will help Celgene maintain leadership in both current and future cancer drugs. King maintained an Outperform rating and $114 on Celgene.

Juno, which went public in December at $38 a share, changed hands recently at $54.80, up more than 18 percent.

Celgene, however, traded at $114.66, off $0.25.

Sanford Bernstein's Geoffrey C. Porges said Celgene's move is likely to ignite "significant debate."

Celgene maintains nearly two dozen mostly smaller development partnerships, but last year agreed to pay $710 million to privately held Nogra Pharma Ltd. to license a drug for Crohn's disease.

"We expect investors to begin to lose patience with Celgene's complex and costly dealmaking," Porges said.

Porges said the "front-loaded" terms of the Juno deal "defy good judgement," but nonetheless maintained an Outperform rating on Celgene and $154 target.

As part of the transaction, Celgene agreed to acquire the $850 million stake in Juno at $93 a share, and can boost its holdings in Juno to up to 30 percent over the 10-year agreement. Celgene will also name a director to Juno's board.

BMO's Jim Birchenough regards the deal as "transformational" for Celgene and maintained an Outperform rating and $163 target.

The transaction adds Juno's CAR-T and TCR technology to Celgene's wider immuno-oncology drug platform, which Birchenough believes is "underestimated."

Latest Ratings for CELG

Nov 2019Standpoint ResearchDowngradesBuyHold
Nov 2019BairdDowngradesOutperformNeutral
May 2019BarclaysDowngradesOverweightEqual-Weight

View More Analyst Ratings for CELG
View the Latest Analyst Ratings


Related Articles (CELG + JUNO)

View Comments and Join the Discussion!

Posted-In: BMO Geoffrey C. Porges JMP Matthew HarrisonAnalyst Color Price Target Reiteration Analyst Ratings Best of Benzinga

Latest Ratings

TSCOMorgan StanleyMaintains170.0
TRVMorgan StanleyMaintains154.0
SLGMorgan StanleyMaintains68.0
ROOTMorgan StanleyMaintains14.0
RNRMorgan StanleyMaintains191.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at